Objective: This study aimed to determine the role of miR-205, miR-182, and miR-183 expression in the serum of ovarian cancer patients in the early diagnosis of ovarian cancer. Materials and Methods: The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was detected in the sera of 101 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 50 healthy volunteers. The results were validated in 98 patients with ovarian cancer, 50 patients with benign ovarian diseases, and 53 healthy volunteers. The expression of miR-205, miR-182, miR-183, CA-125, and HE4 was subjected to ROC analysis and binary logistic regression analysis. Results: The sensitivity of miR-182 and CA-125 was highest (0.901% and 0.832, respectively), but the specificity was low (both 0.27) in the early diagnosis of ovarian cancer. HE4 had the highest specificity in the early diagnosis of ovarian cancer. The sensitivity, specificity, and AUC of HE4 were 0.842, 0.81, and 0.847, respectively. Binary logistic regression analysis showed that three variables were suitable for the diagnostic model: Y=Logit(P)=-5.457+5.365*miR183+0.019*HE4+0.004*CA125. Based on the diagnostic model, ROC analysis showed that the sensitivity, specificity, and AUC were 0.97, 0.85, and 0.951, respectively. Statistical validation showed that the sensitivity, specificity and AUC were 0.941, 0.86, and 0.951, respectively. Conclusion: miR-183 has high specificity and sensitivity in the diagnosis of ovarian cancer. Measurement of miR-183 combined with HE4 and CA-125 is of value for the early diagnosis and evaluation of ovarian cancer.